Larazotide

DB05645InvestigationalSmall molecule

An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.

Mechanism: AT-1001 is an orally administered octapeptide zonulin receptor antagonist that appears to exert its inhibitory effect on gliadin-induced tight junction disassembly by blocking putative zonulin receptors on the luminal surface of the small intestine.
Curator reviewed
Primary indication: Investigated for use/treatment in autoimmune diseases, diabetes mellitus type 1, and gastrointestinal diseases and disorders (miscellaneous).Curator reviewed
Formula / weight: C₃₂H₅₅N₉O₁₀ · 725.845 g/mol (avg)
Also known as: GLYCINE, GLYCYLGLYCYL-L-VALYL-L-LEUCYL-L-VALYL-L-GLUTAMINYL-L-PROLYL- · GLYCYLGLYCYL-L-VALYL-L-LEUCYL-L-VALYL-L-GLUTAMINYL-L-PROLYLGLYCINE
Code names: AT-2347

Resolves to

Compound

UNIIZN3R5560ZVCAS258818-34-7ChEMBLCHEMBL2105646ChEBI177799

Structure

InChIKeyORFLZNAGUTZRLQ-ZMBVWFSWSA-NSMILESCC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O

Targets

P00738HP

What you can answer from here — as of September 19, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

15Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Larazotide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account